Literature DB >> 10755652

Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb.

L L Chappell1, E Dadachova, D E Milenic, K Garmestani, C Wu, M W Brechbiel.   

Abstract

Radioisotopes of Pb(II) have been of some interest in radioimmunotherapy and radioimmunoimaging (RII). However, the absence of a kinetically stable bifunctional chelating agent for Pb(II) has hampered its use for these applications. 203Pb (T(1/2) = 52.02 h) has application potential in RII, with a gamma-emission that is ideal for single photon emission computerized tomography, whereas 212Pb (T(1/2) = 10 h) is a source of highly cytotoxic alpha-particles via its decay to its 212Bi (T(1/2) = 60 min) daughter. The synthesis of the novel bifunctional chelating agent 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra- (2-carbamoyl methyl)-cyclododecane (4-NCS-Bz-TCMC) is reported herein. The Pb[TCMC]2+ complex was less labile to metal ion release than Pb[DOTA]2- at pH 3.5 and below in isotopic exchange experiments. In addition to increased stability to Pb2+ ion release at low pH, the bifunctional TCMC ligand was found to have many other advantages over the bifunctional 1,4,7,10-tetraazacyclodocane-1,4,7,10-tetraacetic acid (DOTA) ligand. These include a shorter and more straightforward synthetic route, a more efficient conjugation reaction to a monoclonal antibody (mAb), with a higher chelate to protein ratio, a higher percent immuroreactivity, and a more efficient radiolabeling reaction of the mAb-ligand conjugate with 203Pb.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755652     DOI: 10.1016/s0969-8051(99)00086-4

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  45 in total

Review 1.  An overview of targeted alpha therapy.

Authors:  Young-Seung Kim; Martin W Brechbiel
Journal:  Tumour Biol       Date:  2011-12-06

2.  A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier.

Authors:  Alicia McFarren; Lillie Lopez; Dionna W Williams; Mike Veenstra; Ruth A Bryan; Aliza Goldsmith; Alfred Morgenstern; Frank Bruchertseifer; Susan Zolla-Pazner; Miroslaw K Gorny; Eliseo A Eugenin; Joan W Berman; Ekaterina Dadachova
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

Review 3.  Bifunctional chelates for metal nuclides.

Authors:  M W Brechbiel
Journal:  Q J Nucl Med Mol Imaging       Date:  2007-11-28       Impact factor: 2.346

Review 4.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

5.  Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Kwamena E Baidoo; Paul S Albert; Karen J Wong; Joseph Flynn; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

6.  Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Authors:  Diane E Milenic; Young-Seung Kim; Kwamena E Baidoo; Karen J Wong; Rachel Barkley; Jose Delgado; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2018-06       Impact factor: 3.099

Review 7.  α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1.

Authors:  Sophie Poty; Lynn C Francesconi; Michael R McDevitt; Michael J Morris; Jason S Lewis
Journal:  J Nucl Med       Date:  2018-03-15       Impact factor: 10.057

Review 8.  Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Authors:  Eszter Boros; Jason P Holland
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

9.  Feasibility of radioimmunotherapy of experimental pneumococcal infection.

Authors:  E Dadachova; T Burns; R A Bryan; C Apostolidis; M W Brechbiel; J D Nosanchuk; A Casadevall; L Pirofski
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-29       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.